News

Chemo Before Surgery Leads to Better Outcomes

(May 28, 2015) A recent study performed in the UK and New Zealand revealed that having chemotherapy treatments before and after surgery is associated with a higher quality of life when compared to those who undergo surgery before chemotherapy. The study, which included 550 women with Stage III or IV... 

OCRF’s Super Saturday Behind the Scenes: An Inside Look

OCRF’s Super Saturday NY, now heading into its 18th year, has long been the summertime event in the Hamptons. And on May 16th, guests on the West Coast will enjoy an unforgettable day of deep discounts, luxury experiences, and activities for the whole family, as OCRF’s Super Saturday LA returns for... 

New Screening Approach Shows Promise

(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the... 

Oophorectomy Increases Breast Cancer Survival in BRCA1 Mutation Carriers

(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study... 

New Recommendations for Ovarian Cancer Prevention

(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer.  Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract here.  MORE

BRCA Cancer Risk Differs With Type and Location of Mutations

(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may... 

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have... 

OCRF Now Accepting Applications for 2016 Research Grants

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.  MORE

The New York Times Publishes OCRF’s Letter to the Editor 3/30/15

In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re... 

Microenvironment Regulates Tumor Suppressor miRNA

Ernst Lengyel, MD, PhD (April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused...